RxDoctor Payments Data

Luna Beck, MD

Internal Medicine · Summerfield, FLNPI 1790742062

Payments from drug & device makers

$2,291in general payments, 2019–2025

Across 118 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$801
  • Lilly USA, LLC$347
  • Amgen$251
  • GSK$197
  • Amarin Pharma, Inc.$175
  • Kowa Pharmaceuticals America, Inc.$105
  • plus $415 from 11 others

What the payments were for

  • Food & beverage$2,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,291 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,009,939
Medicare patients
354
Services billed
39,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$110,043
MounjaroTirzepatide75$88,002
EliquisApixaban52$74,932
ProliaDenosumab33$57,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$51,947
FarxigaDapagliflozin Propanediol26$28,826
Breo ElliptaFluticasone/Vilanterol41$26,377
RybelsusSemaglutide11$20,981
XareltoRivaroxaban11$18,009
TradjentaLinagliptin11$16,108
JanumetSitagliptin Phos/Metformin Hcl13$15,846
TrulicityDulaglutide14$13,354
SynthroidLevothyroxine Sodium72$6,715
Rosuvastatin Calcium306$5,071
Pitavastatin Calcium30$4,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$801$131,025109 claims
Lilly USA, LLCMounjaro, Trulicity$347$101,35689 claims
GSKTrelegy Ellipta, Breo Ellipta$197$78,32490 claims
PfizerEliquis$39$74,93252 claims
AmgenProlia$251$57,07233 claims
AstraZenecaFarxiga$76$28,82626 claims
Johnson & JohnsonXarelto$23$18,00911 claims
Boehringer IngelheimTradjenta$28$16,10811 claims
AbbVieSynthroid$45$6,71572 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Summerfield

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →